丽珠医药(01513.HK)莱康奇塔单抗注射液上市许可申请获受理

阿斯达克财经
Dec 28, 2025

丽珠医药(01513.HK) 公布,控股子公司丽珠单抗收到国家药品监督管理局通知书,丽珠单抗与北京鑫康合联合开发的莱康奇塔单抗注射液境内生产药品注册上市许可申请获受理。拟定适应症用于适合接受系统治疗或光疗的中重度斑块状银屑病成人患者。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-12-24 12:25。)AASTOCKS新闻

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10